Simultaneous LC–MS/MS analysis of eicosanoids and related metabolites in human serum, sputum and BALF

Rhishikesh Thakare, Yashpal S. Chhonker, Nagsen Gautam, Amy Nelson, Richard Casaburi, Gerard Criner, Mark T. Dransfield, Barry Make, Kendra K Schmid, Stephen I. Rennard, Yazen Alnouti

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

The differences among individual eicosanoids in eliciting different physiological and pathological responses are largely unknown because of the lack of valid and simple analytical methods for the quantification of individual eicosanoids and their metabolites in serum, sputum and bronchial alveolar lavage fluid (BALF). Therefore, a simple and sensitive LC–MS/MS method for the simultaneous quantification of 34 eicosanoids in human serum, sputum and BALF was developed and validated. This method is valid and sensitive with a limit of quantification ranging from 0.2 to 3 ng/mL for the various analytes, and has a large dynamic range (500 ng/mL) and a short run time (25 min). The intra- and inter-day accuracy and precision values met the acceptance criteria according to US Food and Drug Administration guidelines. Using this method, detailed eicosanoid profiles were quantified in serum, sputum and BALF from a pilot human study. In summary, a reliable and simple LC–MS/MS method to quantify major eicosanoids and their metabolites was developed and applied to quantify eicosanoids in human various fluids, demonstrating its suitability to assess eicosanoid biomarkers in human clinical trials.

Original languageEnglish (US)
Article numbere4102
JournalBiomedical Chromatography
Volume32
Issue number3
DOIs
StatePublished - Mar 2018

Fingerprint

Eicosanoids
Bronchoalveolar Lavage Fluid
Metabolites
Sputum
Fluids
Serum
Biomarkers
United States Food and Drug Administration
Individuality
Clinical Trials
Guidelines

Keywords

  • COPD
  • LC–MS/MS
  • biomarker
  • eicosanoids

ASJC Scopus subject areas

  • Analytical Chemistry
  • Biochemistry
  • Molecular Biology
  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry

Cite this

Simultaneous LC–MS/MS analysis of eicosanoids and related metabolites in human serum, sputum and BALF. / Thakare, Rhishikesh; Chhonker, Yashpal S.; Gautam, Nagsen; Nelson, Amy; Casaburi, Richard; Criner, Gerard; Dransfield, Mark T.; Make, Barry; Schmid, Kendra K; Rennard, Stephen I.; Alnouti, Yazen.

In: Biomedical Chromatography, Vol. 32, No. 3, e4102, 03.2018.

Research output: Contribution to journalArticle

Thakare, R, Chhonker, YS, Gautam, N, Nelson, A, Casaburi, R, Criner, G, Dransfield, MT, Make, B, Schmid, KK, Rennard, SI & Alnouti, Y 2018, 'Simultaneous LC–MS/MS analysis of eicosanoids and related metabolites in human serum, sputum and BALF', Biomedical Chromatography, vol. 32, no. 3, e4102. https://doi.org/10.1002/bmc.4102
Thakare, Rhishikesh ; Chhonker, Yashpal S. ; Gautam, Nagsen ; Nelson, Amy ; Casaburi, Richard ; Criner, Gerard ; Dransfield, Mark T. ; Make, Barry ; Schmid, Kendra K ; Rennard, Stephen I. ; Alnouti, Yazen. / Simultaneous LC–MS/MS analysis of eicosanoids and related metabolites in human serum, sputum and BALF. In: Biomedical Chromatography. 2018 ; Vol. 32, No. 3.
@article{634ec961434a4cdcbed740b17862bb7a,
title = "Simultaneous LC–MS/MS analysis of eicosanoids and related metabolites in human serum, sputum and BALF",
abstract = "The differences among individual eicosanoids in eliciting different physiological and pathological responses are largely unknown because of the lack of valid and simple analytical methods for the quantification of individual eicosanoids and their metabolites in serum, sputum and bronchial alveolar lavage fluid (BALF). Therefore, a simple and sensitive LC–MS/MS method for the simultaneous quantification of 34 eicosanoids in human serum, sputum and BALF was developed and validated. This method is valid and sensitive with a limit of quantification ranging from 0.2 to 3 ng/mL for the various analytes, and has a large dynamic range (500 ng/mL) and a short run time (25 min). The intra- and inter-day accuracy and precision values met the acceptance criteria according to US Food and Drug Administration guidelines. Using this method, detailed eicosanoid profiles were quantified in serum, sputum and BALF from a pilot human study. In summary, a reliable and simple LC–MS/MS method to quantify major eicosanoids and their metabolites was developed and applied to quantify eicosanoids in human various fluids, demonstrating its suitability to assess eicosanoid biomarkers in human clinical trials.",
keywords = "COPD, LC–MS/MS, biomarker, eicosanoids",
author = "Rhishikesh Thakare and Chhonker, {Yashpal S.} and Nagsen Gautam and Amy Nelson and Richard Casaburi and Gerard Criner and Dransfield, {Mark T.} and Barry Make and Schmid, {Kendra K} and Rennard, {Stephen I.} and Yazen Alnouti",
year = "2018",
month = "3",
doi = "10.1002/bmc.4102",
language = "English (US)",
volume = "32",
journal = "Biomedical Chromatography",
issn = "0269-3879",
publisher = "John Wiley and Sons Ltd",
number = "3",

}

TY - JOUR

T1 - Simultaneous LC–MS/MS analysis of eicosanoids and related metabolites in human serum, sputum and BALF

AU - Thakare, Rhishikesh

AU - Chhonker, Yashpal S.

AU - Gautam, Nagsen

AU - Nelson, Amy

AU - Casaburi, Richard

AU - Criner, Gerard

AU - Dransfield, Mark T.

AU - Make, Barry

AU - Schmid, Kendra K

AU - Rennard, Stephen I.

AU - Alnouti, Yazen

PY - 2018/3

Y1 - 2018/3

N2 - The differences among individual eicosanoids in eliciting different physiological and pathological responses are largely unknown because of the lack of valid and simple analytical methods for the quantification of individual eicosanoids and their metabolites in serum, sputum and bronchial alveolar lavage fluid (BALF). Therefore, a simple and sensitive LC–MS/MS method for the simultaneous quantification of 34 eicosanoids in human serum, sputum and BALF was developed and validated. This method is valid and sensitive with a limit of quantification ranging from 0.2 to 3 ng/mL for the various analytes, and has a large dynamic range (500 ng/mL) and a short run time (25 min). The intra- and inter-day accuracy and precision values met the acceptance criteria according to US Food and Drug Administration guidelines. Using this method, detailed eicosanoid profiles were quantified in serum, sputum and BALF from a pilot human study. In summary, a reliable and simple LC–MS/MS method to quantify major eicosanoids and their metabolites was developed and applied to quantify eicosanoids in human various fluids, demonstrating its suitability to assess eicosanoid biomarkers in human clinical trials.

AB - The differences among individual eicosanoids in eliciting different physiological and pathological responses are largely unknown because of the lack of valid and simple analytical methods for the quantification of individual eicosanoids and their metabolites in serum, sputum and bronchial alveolar lavage fluid (BALF). Therefore, a simple and sensitive LC–MS/MS method for the simultaneous quantification of 34 eicosanoids in human serum, sputum and BALF was developed and validated. This method is valid and sensitive with a limit of quantification ranging from 0.2 to 3 ng/mL for the various analytes, and has a large dynamic range (500 ng/mL) and a short run time (25 min). The intra- and inter-day accuracy and precision values met the acceptance criteria according to US Food and Drug Administration guidelines. Using this method, detailed eicosanoid profiles were quantified in serum, sputum and BALF from a pilot human study. In summary, a reliable and simple LC–MS/MS method to quantify major eicosanoids and their metabolites was developed and applied to quantify eicosanoids in human various fluids, demonstrating its suitability to assess eicosanoid biomarkers in human clinical trials.

KW - COPD

KW - LC–MS/MS

KW - biomarker

KW - eicosanoids

UR - http://www.scopus.com/inward/record.url?scp=85031679223&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85031679223&partnerID=8YFLogxK

U2 - 10.1002/bmc.4102

DO - 10.1002/bmc.4102

M3 - Article

C2 - 28975688

AN - SCOPUS:85031679223

VL - 32

JO - Biomedical Chromatography

JF - Biomedical Chromatography

SN - 0269-3879

IS - 3

M1 - e4102

ER -